A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim11,296 enrolled

Overview

To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).

Study Type

OBSERVATIONAL

Enrollment

11,296

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Olodaterol/Tiotropium BromideDRUG

(Stiolto®) delivered via Respimat inhaler

Umeclidinium/ VilanterolDRUG

(Anoro®) delivered via Ellipta Inhaler

Eligibility

Sex: ALLMin age: 1 YearMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Exclusion Criteria: * Aged \<40 years * Enrolment with medical and pharmacy coverage prior to the cohort entry \< 180 days * Never had COPD diagnosis on the cohort entry date or prior to cohort entry * A record for dispensed Olodaterol/Tiotropium Bromide delivered with Respimat inhalator or Umeclidinium/Vilanterol delivered with the Ellipta Inhaler during the 180-day baseline prior to cohort entry * Diagnosis of asthma any time prior to cohort entry * Diagnosis of lung cancer any time prior to cohort entry * Diagnosis of lung transplant any time prior to cohort entry

Locations (1)

Aetion Inc.

New York, New York, United States

Outcomes

Primary Outcomes

Rate of Discontinuation of Index Treatment (Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol)

The primary outcome of interest was discontinuation of index treatment (Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol), defined as persistence, (i.e. no refill Claim within 60 days \[not including treatment Switch, nor death\] after end of supply) during follow-up. Persistence was assessed by calculating rates of discontinuation in the matched cohorts using a 60-day allowable gap. Rates of discontinuation are reported as the number of events divided by the number of Person-years at risk. Addition of another treatment to index treatment did not count as discontinuation.

Time frame: From first day after the cohort entry date to the earliest occurence of the outcome (discontinuation or refills), or any censoring criteria (365 days of follow-up without discontinuation, death, disenrollment end of data).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.